结核分枝杆菌耐对氨基水杨酸相关基因研究进展  

Progress on Drug Resistance Related Genes of Mycobacterium Tuberculosis to Para-aminosalicylic Acid

作　　者：郭艳[1] 陈玲[1] GUO Yan;CHEN Ling(The Second Department of Respiratory Medicine,the Affiliated Hospital of Zunyi Medical College,Zunyi 563003,China)

机构地区：[1]遵义医学院附属医院呼吸二科,贵州省遵义市563003

出　　处：《实用心脑肺血管病杂志》2018年第11期16-20,共5页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

基　　金：国家自然科学基金资助项目(81760003)

摘　　要：对氨基水杨酸(PAS)是20世纪40年代研发的有效抗结核药物之一,其对结核分枝杆菌具有良好的抑制作用,与其他抗结核药物联用有利于增强其他抗结核药物疗效并减少其他抗结核药物耐药性。目前,PAS仍是世界卫生组织(WHO)推荐的有效抗结核药物之一,主要用于治疗耐多药结核病(MDR-TB)。近年来,结核分枝杆菌对PAS耐药现象逐渐增多,但具体耐药机制尚未完全清楚。本文综述了结核分枝杆菌耐PAS相关基因,旨在为结核分枝杆菌对PAS的耐药机制研究提供参考。Para-aminosalicylic acid(PAS)is one of effective anti-tuberculosis drugs discovered in the 1940s,it has good inhibiting effect on Mycobacterium tuberculosis,may enhance the curative effect of other anti-tuberculosis drugs and reduce the risk of drug resistance,so it is recommended in treating MDR-TB by WHO.In recent years,drug resistance of Mycobacterium tuberculosis to PAS gradually increased,but the specific resistance mechanism is not fully understood.This paper reviewed the drug resistance related genes of Mycobacterium tuberculosis to PAS,in order to provide a reference for the research on resistance mechanism of Mycobacterium tuberculosis to PAS.

关 键 词：结核分枝杆菌 结核 抗多种药物性 广泛耐药结核 对氨基水杨酸 基因 突变 综述 

分 类 号：R378.911[医药卫生—病原生物学] R394.2[医药卫生—基础医学]